Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Limited reported a significant increase in its financial performance for FY25, with operating revenue rising by 56% and SaaS revenue by 95% compared to FY24. The company secured a $10 million strategic investment from Pro Medicus, which will accelerate its commercial pipeline and support the advancement of its CT:VQ™ technology towards regulatory clearance in the U.S. This investment will also aid in expanding production capabilities and enhancing global deployment of its imaging technologies, thereby strengthening 4DMedical’s market position and offering substantial growth opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a respiratory imaging technology company based in Melbourne, Australia, with a focus on developing advanced imaging solutions for lung health. The company offers software-as-a-service (SaaS) products that are used globally across various clinical settings to enhance the diagnosis and management of respiratory conditions.
Average Trading Volume: 800,559
Technical Sentiment Signal: Sell
Current Market Cap: A$109.4M
See more data about 4DX stock on TipRanks’ Stock Analysis page.